ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

VTVT vTv Therapeutics Inc

19.06
0.28 (1.49%)
20 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
vTv Therapeutics Inc VTVT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.28 1.49% 19.06 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
18.74 18.22 20.13 19.06 18.78
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/6/202415:22EDGAR2Form 8-K - Current report
13/6/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/5/202407:00PRNUSCANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE..
09/5/202415:51GLOBEvTv Therapeutics Announces 2024 First Quarter Financial..
09/5/202415:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:28EDGAR2Form 8-K - Current report
19/3/202407:30PRNUSCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA..
13/3/202407:00GLOBEvTv Therapeutics Announces 2023 Fourth Quarter and Full Year..
07/3/202415:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/3/202418:52EDGAR2Form SC 13D - General statement of acquisition of beneficial..
05/3/202407:04EDGAR2Form 8-K - Current report
04/3/202407:00GLOBEvTv Therapeutics Announces FDA Submission for First Phase 3..
01/3/202407:00GLOBEvTv Therapeutics to Participate at the TD Cowen 44th Annual..
28/2/202408:26EDGAR2Form 8-K - Current report
28/2/202408:14EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202407:08EDGAR2Form 8-K - Current report
28/2/202407:00GLOBEvTv Therapeutics Announces $51 Million Private Placement..
22/2/202415:00PRNUSCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO &..
22/12/202315:26EDGAR2Form 8-K - Current report
19/12/202315:28EDGAR2Form 8-K - Current report
12/12/202315:21EDGAR2Form 8-K - Current report
20/11/202315:23EDGAR2Form 8-K - Current report
15/11/202307:22EDGAR2Form 8-K - Current report
15/11/202307:19EDGAR2Form 8-K - Current report
09/11/202315:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:30GLOBEvTv Therapeutics Announces 2023 Third Quarter Financial..
09/11/202315:20EDGAR2Form 8-K - Current report
08/11/202307:00GLOBEvTv Therapeutics to Participate at the Stifel 2023..
02/11/202307:00GLOBEvTv Therapeutics Appoints Thomas Strack, M.D., as Chief..
01/11/202307:24EDGAR2Form 8-K - Current report
01/11/202307:00GLOBEvTv Therapeutics Announces Sale of Shares in Reneo..
27/9/202307:30PRNUSCANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A..
26/9/202307:30PRNUSCantex and Allegheny Health Network Announce Initiation of a..
25/9/202315:20EDGAR2Form DEF 14C - Other definitive information statements
18/9/202307:30PRNUSCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE..
15/9/202315:17EDGAR2Form PRE 14C - Other preliminary information statements
11/8/202315:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202315:36EDGAR2Form 8-K - Current report
11/8/202315:30GLOBEvTv Therapeutics Announces 2023 Second Quarter Financial..
10/8/202307:33PRNUSCantex Pharmaceuticals Announces Article Published in npj..
20/7/202315:22EDGAR2Form 8-K - Current report